Drug Trial Radar · NCT07943520
A Study of SYH2053 Injection in Participants With Hepatic Impairment Compared to Participants With Normal Hepatic Function
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Aug 15, 2026
Primary completion
Aug 15, 2027
Study completion Sep 15, 2027
Sponsor
- Lead sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a Phase I, single-dose, open-label trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of SYH2053 injection in participants with mild, and moderate hepatic impairment compared to participants with normal hepatic function.
Conditions
- Hepatic Impairment
Interventions
SYH2053Drug
SYH2053 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: Pre-dose and multiple timepoints up to 4 days
- Area under the curve of the plasma concentration (AUC) from time 0 to the last measurable time (AUC0-t) and from time 0 extrapolated to infinity (AUC0-inf)Time frame: Pre-dose and multiple timepoints up to 4 days
- Time to reach maximum plasma concentration (Tmax) and terminal half-life (t1/2).Time frame: Pre-dose and multiple timepoints up to 4 days
- Pharmacokinetics: Apparent total clearance (CL/F)Time frame: Pre-dose and multiple timepoints up to 4 days
- Pharmacokinetics: Apparent volume of distribution (Vz/F)Time frame: Pre-dose and multiple timepoints up to 4 days
- Amount excreted unchanged in urine (Ae) of SYH2053 over 72 hours post-doseTime frame: Pre-dose and multiple timepoints up to 4 days
- Fraction excreted (fe) of SYH2053 over 72 hours post-doseTime frame: Pre-dose and multiple timepoints up to 4 days
- Renal clearance (CLr) of SYH2053Time frame: Pre-dose and multiple timepoints up to 4 days
- The serum Low-density lipoprotein cholesterol (LDL-C) levelTime frame: 6 months
- The serum PCSK9 levelTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
the First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.